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Abstract
Aim: To compare oxidative stress in patients with pre-
eclampsia (PE) or intrauterine growth restriction (IUGR)
vs. normal pregnancy (controls) during 48 h after delivery.
Study design: Women with singleton pregnancies were
recruited immediately after delivery (gestational age
)26.0 weeks). Women with PE or IUGR were matched
with healthy controls by age, BMI, gestational age and
delivery mode. Venous blood samples and urine samples
were tested for oxidative stress products 24 h and 48 h
after delivery.
Results: Plasma malondialdehyde (MDA) concentration
24 h after delivery was significantly higher in subjects
with PE or IUGR (3.41"1.14 mmol/L, ns20) than in con-
trols (2.91"0.82 mmol/L, ns38) (Ps0.04). Urine
iPF2a-VI declined from 24 to 48 h after delivery signifi-
cantly in controls (Ps0.006) and not in subjects with PE
or IUGR (Ps0.71).
Conclusion: Of the markers tested only MDA is indicat-
ing higher oxidative stress in women with PE/IUGR than
in normal pregnancy and only at 24 h after delivery. No
consistent pattern of change in the oxidative stress
markers exists between 24–48 h after delivery.
Keywords: Gestational hypertension; isoprostanes;
IUGR; malondialdehyde; oxidative stress; PE; pregnancy.
Introduction
Oxidative stress is defined as an imbalance between free
radical damage and antioxidant protection, caused by
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the presence of free radicals or radical-generating
agents. Oxidative damage belongs to biological sub-
stances such as lipids, DNA and proteins w6x. Lipid
peroxidation products in plasma and urine initiated in pla-
centa through an exaggerated placental production of
superoxide anions (free radicals) are therefore frequently
used biomarkers for oxidative stress.
Pregnancy itself is a condition of increased oxidative
stress due to increased mitochondrial activity and
reduced scavenging potential w32x. Elevated levels of oxi-
dative stress status in pregnancy were shown in many
studies w24x. This status is aggravated in pregnancies
with IUGR or preeclampsia w29x. Preeclampsia accounts
for more than 40% of premature deliveries and is also
the most important cause for maternal mortality and mor-
bidity in developing countries. The maternal endothelium
is the ultimate target leading finally to preeclampsia
where free radicals evoking endothelial-cell activation are
obviously promoters of maternal vascular malfunction.
Oxidative stress may be responsible not only for pre-
eclampsia or IUGR but also for other endothelial cell
generated dysfunctions such as atherosclerosis and car-
diovascular diseases w7, 19, 27x. The fetus as well as the
mother may therefore develop cardiovasuclar problems
after pregnancies with elevated oxidative stress, espe-
cially if oxidative stress persists post-partum w18x.
Indeed, in a study measuring lipid peroxidation products
elevated levels have been found before and also after
delivery in maternal serum from women with PE com-
pared to controls w17x. We hypothesize that pregnancies
associated with elevated oxidative stress such as PE and
IUGR have elevated oxidative stress parameters in blood
and urine during the first 48 h after delivery. The objective
of this study was therefore to measure oxidative stress
markers within the first postpartal 48 h. We focussed
thereby on two markers reflecting oxidative stress gen-
erated from presumably different mechanisms: Malon-
dialdehyde (MDA) in plasma is a product of the reaction
of peroxynitrite with lipids and prostanoids in urine are
generated by non-enzymatic peroxidation of archidonic
acid cleaved into the blood and excreted in the urine
where it reflects oxidative stress in vivo w13, 23x.
Materials and methods
Subjects and protocol
Women who delivered )26.0 gestational weeks at the Depart-
ment of Obstetrics, University Hospital of Zurich, were consec-
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utively recruited during 12 months. Women with normal
pregnancy (controls) were matched by age, BMI, gestational
age, and delivery mode 2:1 to women with high oxidative stress
associated pregnancy, i.e., with preeclampsia (PE) or intrauterine
growth restriction (IUGR). Exclusion criteria were: multiple preg-
nancy, neonatal infection, amnion infection syndrome, CRP
G5 mg/L, BMI G30 kg/m2, gestational diabetes, diabetes mel-
litus, cardiovascular diseases, neoplasia, hepatitis, HIV infection;
nicotine, alcohol and drug abuse. All volunteers gave written
informed consent to participate in this study. BMI was calculated
from the body weight measured between the 6th and 8th week
of gestation (representing the pre-pregnancy weight). Demo-
graphic data are taken from the patient data files. Gestational
age was calculated from the first day of the last menstrual period
and first trimester ultrasound; dates were corrected to the ultra-
sound data where appropriate. PE was defined as gestational
hypertension with a diastolic pressure G90 mmHg taken on two
occasions 6 h apart and proteinuria G300 mg per 24 h and/or
G2q on dipstick analysis of midstream (or catheter) urine spec-
imen according to the criteria of the International Society for the
Study of Hypertension in Pregnancy (ISSHP). IUGR was defined
as gestational related sex-specific birth weight below the 10th
percentile and abnormal Doppler examination w31x.
On the first and on the second post-delivery day (24 and 48 h
after delivery) always at 06:00 after overnight fast, 5 mL of
venous blood were taken to analyze plasma malondialdehyde
concentration. The minimal time between delivery and first blood
sampling had to be 6 h. In addition, the subjects gave two morn-
ing urine samples, each collected between 00:00 a.m. and 06:00
a.m. which were used to measure creatinine and isoprostanes
(8,12- iso-iPF2a-VI and iPF2a-VI).
Analytical methods
Malondialdehyde (MDA) EDTA blood was separated by cen-
trifugation at 48C immediately after blood-withdrawal and plas-
ma samples were stored at –208C until analysis using the Lipid
Peroxidation Assay Kit (Cat. No. 437634) from Calbiochem (VWR
International AG, 8953 Dietikon, Switzerland). The principle of
this colorimetric assay is the reaction of a chromogenic reagent
with MDA at 458C. One molecule of MDA undergoes conden-
sation with two molecules of the reagent to yield a stable chro-
mophore with maximal absorbance at 586 nm. The detection
limit was 0.1 mM MDA and the interassay variation was -5%.
8,12-iso-iPF2a-VI and iPF2a-VI Urine samples were snap-fro-
zen immediately after collection and stored at y808C until fur-
ther analytical procedure. Urine (1 mL), w2H11x-8,12- iso-iPF2a-VI
and w2H11x-iPF2a-VI (1 ng each) were acidified with formic acid to
pH 2.5 and the isoprostanes were extracted twice with 3 mL of
ethyl acetate-hexane (70:30, v/v). After evaporation of the sol-
vent, acetonitrile (80 mL), pentafluorobenzyl bromide (7 mL) and
N,N-diisopropylethylamine (25 mL) were added. The mixture was
allowed to react at 408C for 25 min. The dry sample was purified
by TLC (developing solvent: ethyl acetate-methanol 100:3, v/v).
The zone with an RF 0.2–0.33 was eluted with TLC ethylacetate
(800 mL) and water (50 mL) was added. After centrifugation, the
ethyl acetate phase was withdrawn, the solvent was evaporated
and the isoprostanes derivatized with BSTFA (10 mL; 408C, 1 h).
A 1 mL aliquot of this solution was injected. The isoprostane
concentrations in the prepared urine samples were determined
using gas chromatography/tandemmass spectrometry (GC/MS/
MS). A Finnigan MAT TSQ700 tandem mass spectrometer
equipped with a Varian 3400 gas chromatograph and a CTC
A200S autosampler (Finnigan MAT, Bremen, Germany) was
employed. Gas chromatography of prostanoid derivatives was
carried out on J&W DB-1 (15 m=0.25 mm I.D., 0.25 mm film
thickness) capillary column (MasCom, Bremen, Germany) in the
splitless mode at an inlet pressure of 100 kPa. The oven tem-
perature program for all prostanoids analyzed was as follows:
an initial temperature of 1008C was held for 2 min, and then
increased at 308/min to 2808C and at 58/min to 3108C. This tem-
perature was held for 2 min. The mass spectrometer conditions
were: interface temperature 3008C, source temperature 1508C,
methane CI gas pressure 50 Pa, electron energy 70 eV, emission
current 0.4 mA, conversion dynode 15 kV, electron multiplier
2000 V and the collision cell pressure was 0.2 Pa. For iPF2a-VI
the collision energy was 20 eV and the daughter ions used for
quantification were – wP – (CH3)2SisCH2 – (CH3)2SisOxy (m/z
569.3™ m/z 423.3 for the endogenous iPF2a-VI, m/z 573.3™
m/z 434.2 for the internal standard). For 8,12-iso-iPF2a-VI the
parent ions of the characteristic fragment C6H7O2y (m/z 111.0)
were used: m/z 569.3 for the endogenous 8,12-iso-iPF2a-VI and
m/z 580.4 for the deuterated internal standard. Collision energy
was 28 eV. The urinary isoprostane, iso-iPF2a-VI and 8,12- iso-
iPF2a-VI levels were corrected for creatinine values to eliminate
influences of renal function on the result.
Isoprostanes Urine (100 mL) was diluted with 200 mL water
and tetradeuterated w2H4x-PGF2a (1 ng in 10 mL ethyl acetate)
was added. Sample cleanup and derivatization was as
described for 8,12-iso-iPF2a-VI and iPF2a-VI except TLC: devel-
oping solvent was ethyl acetate-hexane 90:10, v/v) and a broad
zone (RF 0.03–0.39) was eluted with the TLC developing solvent
(1 mL). GC/MS/MS parameters were as depicted for 8,12-iso-
iPF2a-VI and iPF2a-VI, but the collision energy was 12 eV and the
daughter ions used for quantification were wP – 3(CH3)3SiOHxy
(m/z 569.3™m/z 299.3 for the endogenous isoprostanes and
m/z 573.3 ™ m/z 303.2 for the tetradeuterated internal
standard).
Statistics
Statistical analysis was performed using StatView for Windows,
version 5.0.1 (SAS Institute Inc.,  1992–1998, www.statview.
com). A power calculation considering a mean"SD malondial-
dehyde concentration of 2.9"0.4 mmol/L gave a power of 0.80
for ns20 per group. Mean"SD and the median were calculated.
Graphical data are presented with mean"SE. The Kolmogorov-
Smirnov test was used for normality, and the Wilcoxon signed
rank test as well as the paired t-test of log values to detect
longitudinal patterns. Controls vs. PE/IUGR differences were
examined using the Mann-Whitney U-test as well as the unpair-
ed two-tailed t-tests of log values or the Fisher’s exact test,
respectively. Group interaction with other parameters was tested
using analysis of variance (ANOVA). Correlations between two
variables were tested by multiple regression. A P-value -0.05
was considered significant in all tests.
Results
Sixty women were recruited; two women were excluded
because of missing values, resulting in a total of 58
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Table 2 Oxidative stress parameters after delivery.
Parameter Time Controls PE/IUGR P-value
post-delivery (h) (ns38) (ns20)
Malondialdehyde (mmol/L) (plasma) 24 2.91"0.82 3.41"1.14 S (0.04)
48 2.81"0.72 2.92"0.49 NS (0.35)
Isoprostanes (ng/mg)* (urine) 24 71.85"53.39 74.80"42.29 NS (0.74)
48 65.34"34.63 76.37"41.71 NS (0.27)
8,12-iso-iPF2a-VI (ng/mg)* (urine) 24 7.59"4.91 5.29"2.65 NS (0.31)
48 6.50"3.97 5.60"4.22 NS (0.25)
iPF2a-VI (ng/mg)* (urine) 24 1.45"0.80 1.43"0.76 NS (0.54)
48 1.13"0.52 1.22"0.53 NS (0.49)
Mean"SD.
Differences of levels between groups were tested by unpaired two-tailed t-test of log values.
*Corrected for creatinine.
Table 1 Maternal characteristics at delivery.
Controls (ns38) PE/IUGR (ns20) P-value
Age (years) 31.1"5.2 31.9"3.8 0.59
Height (m) 1.64"0.06 1.64"0.06 0.65
Weight (kg) 62.0"10.1 61.0"11.9 0.72
BMI (kg/m2) 23.11"3.24 22.56"4.37 0.59
Nulliparity (n) 18 (47.4) 15 (75) 0.05
Race: caucasian (n) 32 (84.2) 19 (95) 0.4
Delivery mode: c. section (n) 17 (44.7) 13 (65) 0.17
Gestational age (weeks) 37.2"2.9 35.8"3.5 0.11
Preeclampsia (n) 0 (0) 8 (40) 0.0005
Birth weight (g) 3134"778 2104"698 -0.0001
Birth weight centile -10 (n) 0 (0) 14 (70) -0.0001
Placental weight (g) 568.0"184.9 369.4"126.5 0.0001
Continuous values: mean"SD; numeric values: n (%).
Differences between groups were tested by unpaired two-tailed t-test or two-tailed Fisher’s exact test, respectivety.
women (ns20 with PE, IUGR, and ns38 controls). The
groups were similar with regard to age, BMI, race, and
delivery mode, but different with regard to preeclampsia,
birth or placental weight; seventeen newborns of the PE/
IUGR group had a birth weight below the 5th percentile
(Table 1). No significant difference exists between demo-
graphic data of women with PE and such with IUGR (data
not shown). Mean interval between delivery and blood
(begin of urine) sampling for both groups was 20.2 h (so
called 24 h time point) and 44.2 h after delivery (so called
48 h time point).
Malondialdehyde (MDA) plasma concentration was
significantly elevated 24 h after delivery in women who
had pregnancy with PE and/or IUGR (Ps0.04), whereas
the levels of the other parameters were not significantly
different either at 24 or at 48 h after delivery compared
to controls (Table 2). In the whole collective, all parame-
ters declined from 24 to 48 h after delivery. However, if
groups were considered, only MDA and iPF2a-VI levels
changed significantly between 24 and 48 h: differences
between MDA plasma levels were significant in women
with PE/IUGR but not in controls (Ps0.04) (Figure 1), and
iPF2a-VI declined significantly from 24 to 48 h only in
women with normal pregnancy (Ps0.006) but not in
women with PE/IUGR (Figure 2). No intra-group differ-
ences in oxidative stress parameters were found if results
from women with PE alone (ns6) were compared to that
from women with IUGR alone (ns14). Multiple regression
analysis did not show any additional influence of parity
or delivery mode on the demonstrated differences.
Comment
We could show that malondialdehyde plasma concentra-
tion was significantly elevated in women with PE or IUGR
24 h after delivery and iPF2a-VI declined less from 24 to
48 h after delivery in comparison to healthy women with
normal pregnancy.
Oxidative stress parameters vary significantly if they
are not measured under standardized conditions. Known
influencing factors are BMI, age, gestational age, CRP,
food and drug intake as well as diurnal variations w4, 9,
16, 22x. We have considered these problems in our study
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Figure 1 Post-delivery malondialdehyde plasma concentra-
tions. Women with PE/IUGR had significantly elevated malon-
dialdehyde levels 24 h after delivery compared to women with
normal pregnancy (*Ps0.04). Difference of levels between 24
and 48 h was significant in women with PE/IUGR (Ps0.04).
Figure 2 Post-delivery iPF2a-VI levels in urine. Women with
PE/IUGR did not differ significantly from women with normal
pregnancy. Difference of levels between 24 and 48 h was sig-
nificant only in controls (Ps0.006).
design by using strong inclusion and exclusion criteria,
by matching women with PE/IUGR with controls and
by standardizing blood and urine sampling. Although
matching by gestational age was performed as carefully
as possible, we could not avoid that gestational age was
insignificantly higher in the control group. However, this
is a known problem in studies like the present one to
select appropriate controls. Moreover, as other authors
before w10, 29x, we have not shown separate data for
women with PE and for such with IUGR. This study
design was applied because most of our women with PE
have reduced intrauterine growth. Indeed, in our sub-
group of women with PE (ns8) there were two women
with IUGR and five women with birth weights at percen-
tiles )10F50.
Malondialdehyde (MDA) in plasma and prostanoids in
urine corrected for creatinine are the most reliable mark-
ers for in vivo oxygen stress reflecting lipid peroxidation
w2, 23x. MDA results from peroxidation of peroxynitrite
with lipids w30x. In women with PE, MDA levels are ele-
vated in placental tissue, in maternal plasma, in umbilical
cord blood erythrocytes, as well as in the placental tissue
w1, 5, 12, 13, 28x. It seems that oxygen damage in the
placenta is mediated by increased MDA production fol-
lowed by higher levels also in the maternal (and umbilical)
circulation. The severity does correlate with both, the
MDA concentration in the serum and that in the eryth-
rocytes w26x. Accordingly, it was shown that the greater
the level of lipid peroxidation, the greater the severity of
PE w20x. Indeed, we have found in our study the highest
MDA levels 24 h after delivery in women with PE
(3.55 mmol/L; ns8; data not shown). Controls did not
change MDA levels after delivery; moreover, mean values
were similar (2.91 mmol/L at 24 h and 2.81 mmol/L at
48 h) as that found in non-pregnant healthy, overnight
fasted, controls from our recent study with the same
MDA assay (2.88 mmol/L) w25x.
Isoprostanes (or F2-isoprostanes) are isomers of PGF2a
and free-radical catalyzed products of non-enzymatic
lipid peroxidation of arachidonic acid. They are chemi-
cally stable, formed in situ at the side of the free-radical
attack, and are cleaved from the plasma membrane and
excreted in urine. Isoprostanes have been shown to be
elevated in a number of disorders that are possibly asso-
ciated with oxidative stress reflecting oxidative stress in
vivo w23x. However, data about isoprostane levels in PE
are controversial. F2-isoprostanes were elevated in plas-
ma, but not in urine or in saliva w14, 15x. Otherwise, no
difference in 8-iso-PGF2a in plasma or urine w18x or in
8,12-iso-iPF2a-VI (urine only) was found in PE w22x. Sig-
nificant difference in redox-related molecules has been
found in placenta from pregnancies with PE and/or IUGR
compared to controls w29x. Isoprostanes in amniotic fluid
taken during amniocentesis at 15–18 weeks also pre-
dicted IUGR; it distinguished between normal pregnan-
cies and those with SGA (birth weight below the 5th
percentile) with a sensitivity of 100% and a specificity of
72% w11x. Moreover, in a study of 78 women, elevated
and similar values of 8-iso-PGF2a were found in maternal
plasma of women with gestational hypertension or with
IUGR compared to that with normal pregnancies, respec-
tively w10x. Elevated maternal plasma levels of isopros-
tanes were also found by Harsem et al. 2006 w8x. Our
results indicate no significant difference in urinary iPF2a-
VI level between the high stress associated group and
women with normal pregnancy. iPF2a-VI declined less
from 24 to 48 h after delivery, but the pattern of change
from 24 to 48 h was not consistent.
Oxidative stress in pregnancy may induce micro-dam-
age to maternal arteries and might be a link to adverse
maternal long-term morbidity such as atherosclerosis or
cardiovascular diseases w7, 19, 27x. It was hypothesized
that not only the mother is influenced by oxidative stress
but that these damages can have long lasting impacts
on the unborn baby (Barker’s hypothesis of ‘‘Fetal Pro-
gramming’’) w2, 21x. Until now only one in vivo study
focussed on post-delivery lipid peroxidation products:
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Thiobarbituratic acid reactive substances are reported to
be elevated in maternal serum before and also after deliv-
ery in women with PE compared to normal women w17x.
In summary, we demonstrated that of the markers test-
ed, only MDA indicated higher oxidative stress in women
with PE/IUGR and only at 24 h after delivery. No consis-
tent pattern of change in the oxidative stress markers
exists between 24 to 48 h after delivery. In cases of PE/
IUGR, MDA levels in maternal plasma, in contrast to urine
isoprostane levels, may reflect oxidative damage in the
placenta which spills-over to the maternal circulation
from where it will be eliminated with time.
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